PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

NEW YORK, May 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01171153/PharmaPoint-Multiple-Sclerosis---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Similar to India, China has a low prevalence of MS, despite its large population. However, a large proportion of physicians surveyed in this report still use the Poser criteria, which relies almost exclusively on clinical examination. Therefore, given the lack of sensitive tools, such as MRI, to aid in diagnosis, it is highly possible that the actual size of the MS population in China is significantly underestimated. The key drivers of growth in this market include government initiatives to increase healthcare access, the increased availability of advanced diagnostic tools due to strong economic growth in the country, as well as the launch of new oral DMTs. These factors are expected to collectively enhance treatment rates during the forecast period.

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Classification of Multiple Sclerosis 15
3.2 Symptoms 17
3.2.1 Prognosis 18
3.2.2 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis 20
4.2 Treatment Overview 23
4.2.1 Management of Acute Relapse 24
4.2.2 Treatment with Disease-Modifying Therapies 24
4.2.3 Symptomatic Therapies 27
4.3 China 28
4.3.1 Diagnosis 28
4.3.2 Clinical Practice 28
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles – Major Brands 33
5.3.1 Betaseron/Betaferon (interferon beta-1b) 33
5.3.2 Avonex (interferon beta-1a) 38
5.3.3 Rebif (interferon beta-1a) 43
5.3.4 Copaxone (glatiramer acetate; copolymer-1) 47
5.3.5 Tysabri (natalizumab) 51
5.3.6 Gilenya/Imusera (fingolimod; FTY720) 56
5.3.7 Aubagio (teriflunomide) 61
5.3.8 Other Disease–Modifying Therapies 66
6 Opportunity and Unmet Need 67
6.1 Overview 67
6.2 Unmet Needs 68
6.2.1 Currently Available MS Drugs Only Provide Partial Benefits 68
6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 69
6.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 70
6.2.4 Effective Treatments for Progressive MS Are Still Elusive 71
6.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 72
6.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 73
6.3 Unmet Needs Gap Analysis 74
6.4 Opportunities 75
6.4.1 Treatments for Progressive MS 75
6.4.2 Targeting Patients with Clinically Isolated Syndrome 75
7 Pipeline Assessment 76
7.1 Overview 76
7.2 Promising Drugs in Clinical Development 78
7.2.1 BG-12 (dimethyl fumarate; BG00012) 80
7.2.2 Lemtrada (alemtuzumab) 85
7.2.3 Laquinimod (ABR-215062) 91
7.2.4 Daclizumab High-Yield Process (HYP) 96
7.2.5 Ocrelizumab (RG1594) 101
7.2.6 Siponimod (BAF-312) 106
7.2.7 NU-100 (interferon beta-1b) 110
7.2.8 Masitinib (AB-1010) 114
7.2.9 Tcelna (imilecleucel-T) 118
8 Market Outlook 122
8.1 China 122
8.1.1 Forecast 122
8.1.2 Key Events 125
8.1.3 Drivers and Barriers 125
9 Appendix 127
9.1 Bibliography 127
9.2 Abbreviations 138
9.3 Methodology 142
9.4 Forecasting Methodology 142
9.4.1 Diagnosed MS patients 142
9.4.2 Percent Drug-Treated Patients 143
9.4.3 Drugs Included in Each Therapeutic Class 143
9.4.4 General Pricing Assumptions 144
9.4.5 Individual Drug Assumptions 145
9.4.6 Generic Erosion 149
9.4.7 Pricing of Pipeline agents 149
9.5 Physicians and Specialists Included in This Report 150
9.6 Primary Research – Prescriber Survey 151
9.7 About the Authors 152
9.7.1 Analysts 152
9.7.2 Global Head of Healthcare 153
9.8 About GlobalData 154
9.9 Contact Us 154
9.10 Disclaimer 154

List of Tables

Table 1: Common Presenting Symptoms of Multiple Sclerosis 17
Table 2: Factors That Can Affect Prognosis in Multiple Sclerosis 18
Table 3: Revised 2010 McDonald Criteria for the Diagnosis of Multiple Sclerosis 21
Table 4: Treatment Guidelines for Multiple Sclerosis 23
Table 5: Top Three Disease-Modifying Therapies Prescribed for Multiple Sclerosis by Market 25
Table 6: Pharmacotherapy for Common Multiple Sclerosis Symptoms 27
Table 7: Disease-Modifying Drugs for the Treatment of Multiple Sclerosis, 2012 32
Table 8: Product Profile – Betaseron 34
Table 9: Betaseron/Betaferon SWOT Analysis, 2012 37
Table 10: Product Profile – Avonex 39
Table 11: Avonex SWOT Analysis, 2012 42
Table 12: Product Profile – Rebif 44
Table 13: Rebif SWOT Analysis, 2012 46
Table 14: Product Profile – Copaxone 48
Table 15: Copaxone SWOT Analysis, 2012 50
Table 16: Product Profile – Tysabri 52
Table 17: Tysabri SWOT Analysis, 2012 55
Table 18: Product Profile – Gilenya 57
Table 19: Gilenya SWOT Analysis, 2012 60
Table 20: Product Profile – Aubagio 62
Table 21: Aubagio SWOT Analysis, 2012 65
Table 22: Summary of Alternative MS DMTs, 2012 66
Table 23: Overall Unmet Needs – Current Level of Attainment 67
Table 24: Clinical Unmet Needs – Gap Analysis, 2012 74
Table 25: Multiple Sclerosis – Phase Pipeline, 2012 78
Table 26: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 79
Table 27: Product Profile – BG-12 81
Table 28: BG-12 SWOT Analysis, 2012 84
Table 29: Product Profile – Lemtrada 86
Table 30: Lemtrada SWOT Analysis, 2012 90
Table 31: Product Profile – Laquinimod 92
Table 32: Laquinimod SWOT Analysis, 2012 95
Table 33: Product Profile – Daclizumab High-Yield Process 96
Table 34: Daclizumab SWOT Analysis, 2012 100
Table 35: Product Profile – Ocrelizumab 102
Table 36: Ocrelizumab SWOT Analysis, 2012 105
Table 37: Product Profile – Siponimod 106
Table 38: Siponimod SWOT Analysis, 2012 109
Table 39: Product Profile – NU-100 111
Table 40: NU-100 SWOT Analysis, 2012 113
Table 41: Product Profile – Masitinib 114
Table 42: Masitinib SWOT Analysis, 2012 117
Table 43: Product Profile – Tcelna 119
Table 44: Tcelna SWOT Analysis, 2012 121
Table 45: Sales Forecasts ($m) for Multiple Sclerosis in China, 2012–2022 123
Table 46: Key Events Impacting Sales for Multiple Sclerosis in China, 2012 125
Table 47: Multiple Sclerosis Market in China – Drivers and Barriers, 2012 125
Table 48: Physicians Surveyed, By Country 151

List of Figures

Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis 16
Figure 2: Expanded Disability Status Scale (EDSS) 22
Figure 3: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies 26
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012–2022 78
Figure 5: Sales for Multiple Sclerosis in China by Drug Class, 2012-2022 124

To order this report:
Pathology Industry: PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker